Healx Ltd. news
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part of the reason why
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, is proud to announce that world-renowned computational drug discovery expert, Nathan Brown, has joined the team as Director of Digital Chemistry.
Nathan joins from BenevolentAI, where he led the Cheminformatics team and was responsible for the research and development of new and effective approaches for computational drug design. Globally
Ovid Therapeutics (NASDAQ:OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced that Healx has secured from O
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. Knowledge limitations around rare conditions are a huge barrier to treatment development and are compounded by the fact that rare disease patient populations are often small and geographically dispersed.
Registries collect information about individuals who are affected by a specific condition and a